Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Open-label Observation of Oral Hexavalent Reassorted Rotavirus Live Attenuated Vaccine (Vero Cell) in Healthy Adults and Children, as Well as the Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity in Healthy Infants

Trial Profile

The Open-label Observation of Oral Hexavalent Reassorted Rotavirus Live Attenuated Vaccine (Vero Cell) in Healthy Adults and Children, as Well as the Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity in Healthy Infants

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rotavirus vaccine (Primary)
  • Indications Rotavirus infections
  • Focus Adverse reactions
  • Sponsors Sinovac Biotech

Most Recent Events

  • 05 May 2025 Status changed from recruiting to active, no longer recruiting.
  • 16 Aug 2024 According to SINOVAC media release, company anticipates by the first half of 2024, this trial has finished enrollment and vaccination of adults and children participants, and enrollment of infants participants is ongoing and expected to be finished in the third quarter of 2024.
  • 07 May 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top